In both CAR T groups (ARMed and not), human T cells could still be detected 29 days post-infusion (Supplementary Figure S5D), demonstrating that CAR T cell persistence in the periphery is not sufficient to confer anti-tumor CAR T function in this model of PD1-PDL1 mediated immune suppression, and that T cell function against peripheral tumors could be improved by administration of CPI Abs. Here, PDCD1 is linked to neoplasm.